2.7% (n = 2) of PD patients remained medication naïve throughout the 12-month follow-up, whilst 89.2% utilized oral levodopa, 25.7% a dopamine agonist, 18.9% a monoamine oxidase inhibitor, 12.2% an anticholinergic, 16.2% a catechol-O-methyl transferase inhibitor, 9.5% amantadine, whereas utilization of existing DAT included 1.4% apomorphine subcutaneous infusions, 9.5% LCIG and 12.2% DBS. Here, SLC6A3 is linked to Parkinson disease.